Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study

Title: ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study
Authors: Kandane-Rathnayake, R; Louthrenoo, W; Hoi, A; Luo, SF; Wu, YJJ; Chen, YH; Cho, J; Lateef, A; Hamijoyo, L; Navarra, SV; Zamora, L; Sockalingam, S; An, Y; Li, Z; Katsumata, Y; Harigai, M; Hao, Y; Zhang, Z; Kikuchi, J; Takeuchi, T; Basnayake, BMDB; Chan, M; Ng, KPL; Tugnet, N; Kumar, S; Oon, S; Goldblatt, F; O’Neill, S; Gibson, KA; Ohkubo, N; Tanaka, Y; Bae, SC; Lau, CS; Nikpour, M; Golder, V; Morand, EF
Publisher Information: BMC
Publication Year: 2022
Collection: The University of Melbourne: Digital Repository
Description: BACKGROUND: The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. METHODS: Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K ≥10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). RESULTS: A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], p
Document Type: article in journal/newspaper
Language: English
ISSN: 1478-6354
Relation: https://hdl.handle.net/11343/306426
Availability: https://hdl.handle.net/11343/306426
Rights: https://creativecommons.org/licenses/by/4.0 ; CC BY
Accession Number: edsbas.5C0BE45B
Database: BASE